ライフサイエンスコーパス: clodronate

1 tive intratracheal instillation of liposomal clodronate.

2 y subconjunctival (SC) delivery of liposomal clodronate.

3 gues and the antimacrophage agent, liposomal clodronate.

4 etion of alveolar macrophages with liposomal clodronate.

5 IL17RA(-/-) mice using liposomes loaded with clodronate.

6 y treating B6 mice with liposomes containing clodronate.

7 n after macrophage depletion using liposomal clodronate.

8 hibited by the antiosteolytic bisphosphonate clodronate.

9 travenous injection of liposome-encapsulated clodronate.

10 effects were indistinguishable from those of clodronate.

11 antiresorptive and antimacrophage effects of clodronate.

12 ) group 5 = diabetes + periodontitis + LDD + clodronate.

13 is-free interval was slightly increased with clodronate (0.74, 0.55-1.00; p=0.047).

14 Patients were randomized to receive oral clodronate 1,600 mg/d or a placebo for 2 years starting

15 acid (4 mg intravenously every 6 months) or clodronate (1,600 mg/d orally) be considered as adjuvant

16 domly assigned in a 1:1 ratio to either oral clodronate 1600 mg daily for 3 years (n=1662) or placebo

17 igned to take four tablets per day of sodium clodronate (2080 mg) or matching placebo for up to 3 yea

18 ld C57BL/10J mice with liposome-encapsulated clodronate 48 h before 35 min of hepatic ischemia with b

19 ither phosphate-buffered saline (control) or clodronate (a macrophage depleting drug) at 15 weeks pos

20 re-treatment of the recipient with liposomal clodronate, a macrophage depleting agent, with the goal

21 Conversely, in mice with clodronate-ablated macrophages, neutrophils extravasate,

22 Systemic depletion of macrophages with clodronate abolished CDC-mediated cardioprotection.

23 c cells by injection of liposomes containing clodronate abolished diabetes, although inflammation rem

24 M using intracerebroventricular injection of clodronate abrogates the reactive oxygen species product

25 cant benefits for zoledronic acid (ZOL) over clodronate acid (CLO) were seen in the Medical Research

26 Both EGTA and clodronate also prevented the bisphosphonate-induced inh

27 owever, treatment with liposome-encapsulated clodronate, an agent that depletes macrophages in vivo,

28 controlled trials assessed the use of sodium clodronate, an oral, first-generation bisphosphonate.

29 To compare the mechanism of action of clodronate and alendronate, effects on protein prenylati

30 The effects of clodronate and AppCCl2p on bone resorption, osteoclast n

31 Clodronate and DTR inhibited macrophage infiltration and

32 Two potent inhibitors, clodronate and etidronate, are already clinically approv

33 Unlike alendronate, clodronate and its metabolite did not affect prenylation

34 The use of mono and combined clodronate and LDD administrations may significantly red

35 evaluate the effect of mono and combined BP clodronate and LDD therapies in reducing gingival levels

36 aims of this study were to determine whether clodronate and liposome-encapsulated clodronate are meta

37 ause there are no direct comparisons between clodronate and pamidronate or zoledronic acid, the super

38 Most studies evaluated zoledronic acid or clodronate, and data are extremely limited for other bis

39 were depleted from mice by administration of clodronate, and their location and phenotype were examin

40 y the positive result of one trial of sodium clodronate, and we found no evidence of a benefit from t

41 x vivo with immunomagnetic beads) metabolize clodronate, and whether rat peritoneal macrophages metab

42 LDD; 4) group 4 = diabetes + periodontitis + clodronate; and 5) group 5 = diabetes + periodontitis +

43 whether clodronate and liposome-encapsulated clodronate are metabolized to adenosine 5'-(beta,gamma-d

44 ronate, risedronate, and lovastatin, but not clodronate, are blocked by geranylgeraniol, a precursor

45 acerebral injection of liposome-encapsulated clodronate at P5 significantly reduced vessel coverage a

46 he intratracheal administration of liposomal clodronate attenuated particulate matter-induced IL-6 pr

47 B6) mice by i.v. administration of liposomal clodronate before allogeneic bone marrow transplantation

48 in the airways were depleted using liposomal clodronate before infection, this resulted in a signific

49 ection of the macrophage-depleting liposomal clodronate before radiotherapy can increase the antitumo

50 acerebral injection of liposome-encapsulated clodronate before transient middle cerebral artery occlu

51 nd could be inhibited by addition of EGTA or clodronate, both of which chelate calcium ions.

52 Pretreatment of NTN mice with clodronate but not control liposomes completely prevente

53 protocol B-34 aims to ascertain whether oral clodronate can improve outcomes in women with primary br

54 Liposome-encapsulated clodronate caused an increase in peritoneal macrophage a

55 gimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960 patients with newly diagnosed m

56 ence of improvement in overall survival with clodronate compared with placebo (HR 1.12, 0.89-1.42; p=

57 e with metastatic disease from use of sodium clodronate compared with placebo was seen in overall sur

58 ippostrongylus brasiliensis and treated with clodronate-containing liposome to deplete macrophages or

59 capsular sinus CD169-positive macrophages by clodronate-containing liposome was associated with a lac

60 Thus, we predicted that injection of clodronate-containing liposomes (CLs), which selectively

61 rophages using subconjunctival injections of clodronate-containing liposomes before corneal infection

62 Depletion of macrophages by clodronate-containing liposomes blocked the tumor-promot

63 normally developed spleens by treatment with clodronate-containing liposomes demonstrated that these

64 Clodronate-containing liposomes deplete mice of splenic

65 macrophages by intranasal administration of clodronate-containing liposomes in caspase-9 inhibitor-t

66 In vitro, clodronate-containing liposomes killed activated murine

67 Mice treated with clodronate-containing liposomes show markedly less tumor

68 ed mice and compared tumor development using clodronate-containing liposomes to deplete macrophages i

69 Treatment of PVC-211 MuLV-infected rats with clodronate-containing liposomes, which specifically kill

70 phages were depleted from ilea of mice using clodronate-containing liposomes.

71 Clodronate depletion of circulating monocytes, by contra

72 Liposomally encapsulated clodronate (dichloromethylene diphosphonate) has previou

73 splenic phagocytic APCs by i.v. injection of clodronate- (dichloromethylene diphosphonate) containing

74 ages by intranasal instillation of liposomal clodronate diminished pneumococcal clearance.

75 ival administration of liposome-encapsulated clodronate efficiently diminished resident ocular surfac

76 al macrophages with the macrophagicidal drug clodronate eliminated the latex beads' protective effect

77 peritoneal macrophages after depletion with clodronate encapsulated liposomes.

78 Macrophage ablation by injection of clodronate-encapsulated liposomes increases blood platel

79 hamsters were treated, intratracheally, with clodronate-encapsulated liposomes or control liposomes a

80 Treatment with clodronate-encapsulated liposomes resulted in significan

81 Some mice were also given clodronate-encapsulated liposomes to deplete macrophages

82 macrophages metabolize liposome-encapsulated clodronate, following in vivo administration.

83 s or older on study entry showed benefits of clodronate for recurrence-free interval (0.75, 0.57-0.99

84 l);Pkhd1-Cre mice by treating with liposomal clodronate from postnatal day 10 until day 24.

85 Clodronate, given to patients with primary operable brea

86 tion was noted in 23 of 1612 patients in the clodronate group and 12 of 1623 patients in the placebo

87 ence to treatment at 3 years was 56% for the clodronate group and 60% for the placebo group.

88 -4 diarrhoea was noted in 28 patients in the clodronate group and in ten in the placebo group.

89 not differ between groups (286 events in the clodronate group vs 312 in the placebo group; hazard rat

90 ible case of osteonecrosis of the jaw in the clodronate group.

91 at a first-generation bisphosphonate, sodium clodronate, improves overall survival in men with metast

92 ZOL is preferred over oral clodronate in newly diagnosed patients with MM because o

93 e infiltration by systemic administration of clodronate-incorporated liposomes fails to suppress LSI-

94 Clodronate-induced depletion of the alveolar macrophage

95 Consistent with these findings, clodronate-induced macrophage depletion results in a sig

96 Importantly, clodronate-induced macrophage depletion significantly at

97 Interestingly, macrophage depletion with clodronate inhibited the development of colitis, while t

98 lvaria also is blocked by mevalonate whereas clodronate inhibition is not.

99 re generated by the combination of liposomal clodronate injection, irradiation, and BM transplantatio

100 lled trials is modest but supports that oral clodronate, intravenous pamidronate, and intravenous zol

101 ted CCR2 chimeric mice by the combination of clodronate, irradiation, and bone marrow (BM) transplant

102 Clodronate is an alternative bisphosphonate approved wor

103 hese results provide proof-of-principle that clodronate is effective at sparing the number of donor B

104 Additionally, clodronate is not available in the United States.

105 somiasis with macrophage-depleting liposomal clodronate (LC) to define how macrophages mediate bladde

106 n the bladder by administration of liposomal clodronate led to higher UPEC burdens.

107 in the induction of LPC proliferation using clodronate liposome deletion of Kupffer cells and adopti

108 Interestingly, using a clodronate liposome model with targeted depletion of mat

109 Lastly, clodronate liposome treatment of TCR transgenic mice dep

110 Clodronate liposome treatment reduced initial liver mono

111 Clodronate liposome treatment significantly reduced the

112 atment or peripheral macrophage depletion by clodronate liposome treatment.

113 g on day 1, which was virtually abolished by clodronate liposome treatment.

114 Depleting macrophages (with clodronate liposome) and neutrophils (with anti-Ly6G/1A8

115 phages, through subconjunctival injection of clodronate liposome, attenuated lissamine green staining

116 Clodronate liposome-mediated depletion of infiltrating m

117 Clodronate liposome-mediated depletion of islet macropha

118 ost-AAI rAMs was studied in vivo by means of clodronate liposome-mediated depletion, adoptive transfe

119 ndent of lymphoid tissues but dependent on a clodronate liposome-sensitive population of liver-reside

120 AFIA mice had reduced CD68(+) cells, whereas clodronate liposome-treated mice had increased CD68(+) a

121 tion of these infiltrating macrophages using clodronate-liposome administration shows a significant r

122 Clodronate-liposome treatment depletes circulating monoc

123 The enhancing effect of clodronate-liposome treatment on infection (i) was shown

124 In clodronate-liposome-treated group, allograft hearts exhi

125 rophage depletion was achieved by daily i.v. clodronate liposomes (-1 day to +3 days) during AngII in

126 Antecedent Kupffer cell depletion with clodronate liposomes (0.5 mg/kg).

127 onducted to determine whether treatment with clodronate liposomes (CL(2)MDP-lip), which cause depleti

128 nvestigate this, we depleted phagocytes with clodronate liposomes (CL) in vivo through systemic deliv

129 Moreover, depletion of SCS macrophages using clodronate liposomes abolished NK cell accumulation and

130 In addition, the treatment of rats with clodronate liposomes depleted KCs and led to increased s

131 Importantly, the application of clodronate liposomes effectively depleted splenic and CN

132 ction, we depleted them by the inhalation of clodronate liposomes in an established mouse model of re

133 Depletion of phagocytic cells by clodronate liposomes in wild-type mice resulted in a red

134 Clodronate liposomes increased efferocytosis (clearance

135 th saline/WT, which was virtually ablated by clodronate liposomes independent of hypertension.

136 was assessed by eliminating these cells with clodronate liposomes or silica.

137 pletion of alveolar macrophages with inhaled clodronate liposomes reduced both NK and T cell numbers

138 The depletion of blood monocytes with clodronate liposomes reduced neutrophil clustering in th

139 However, Kupffer cell depletion with clodronate liposomes resulted in greater apoptosis and F

140 phage depletion in wild-type (WT) mice using clodronate liposomes resulted in impaired muscle regener

141 using splenectomized mice or treatment with clodronate liposomes suggested that macrophages in the s

142 apoE-/- mice before and after treatment with clodronate liposomes to deplete tissue macrophages, comp

143 effects were mitigated in mice treated with clodronate liposomes to reduce circulating monocytes and

144 peritoneal macrophages were depleted (using clodronate liposomes) from PD-1(-/-) mice, the animals'

145 epletion of macrophages in the cornea (using clodronate liposomes) prior to injury significantly inhi

146 rone mice SNF(1) mice that were treated with clodronate liposomes, but not mice treated with vehicle,

147 is in vivo, induced by the administration of clodronate liposomes, can exacerbate the autoimmune phen

148 By selective depletion studies using clodronate liposomes, depleting monoclonal antibodies sp

149 s were not affected following treatment with clodronate liposomes, immunization of CCR2(-/-) mice, or

150 mice that had been macrophage depleted using clodronate liposomes.

151 mice depleted of alveolar macrophages using clodronate liposomes.

152 ated by alveolar macrophage depletion, using clodronate liposomes.

153 . bilis-infected Rag2(-/-) mice treated with clodronate liposomes.

154 Depletion of macrophages by clodronate-liposomes abrogates liver EphB2 messenger RNA

155 significantly elevated in mice treated with clodronate-liposomes at 3 and 5 days p.i., while IL-10 l

156 elevated in the cornea of mice treated with clodronate-liposomes at both 3 and 5 days p.i.

157 The elimination of macrophages by clodronate-liposomes attenuated NF-kappaB-induced liver

158 Both groups of inbred mice treated with clodronate-liposomes compared with PBS-liposomes (contro

159 Treatment with clodronate-liposomes did not affect the antigen-presenti

160 inactivation of monocyte lineage cells with clodronate-liposomes led to the suppression of pathologi

161 this monocytic cell population, using either clodronate-liposomes or gadolinium chloride, prevented p

162 and selective depletion of macrophages with clodronate-liposomes protects hearts against allograft r

163 Macrophage depletion using clodronate-liposomes resulted in a significant reduction

164 were determined in BALB/c mice treated with clodronate-liposomes vs control-treated mice.

165 e cornea of both groups of mice treated with clodronate-liposomes vs PBS-liposomes.

166 cterial plate counts in B6 mice treated with clodronate-liposomes were unchanged at 3 days and were h

167 methylene diphosphonate (Cl2MDP-liposomes or clodronate-liposomes) before priming mice with vesicular

168 elevated in both groups of mice treated with clodronate-liposomes.

169 depleted by treating recipient animals with clodronate-liposomes.

170 xpansion was abrogated by prior injection of clodronate-loaded liposomes, indicating a role for subca

171 phoma depletion by CD20 mAb in vivo, whereas clodronate-mediated depletion of macrophages eliminated

172 Clodronate-mediated depletion of phagocytic cells marked

173 At day 30, liposomal clodronate-mediated macrophage depletion reduced fibrosi

174 Liposomal clodronate-mediated macrophage depletion significantly r

175 iven to patients with primary breast cancer, clodronate might reduce the subsequent incidence of bone

176 In vivo, MPhi depletion (clodronate, MPhi Fas-induced apoptosis mice) and genetic

177 rrence of nonosseous metastases was similar (clodronate, n = 112; placebo, n = 128; P =.257), but the

178 uction in the occurrence of bone metastases (clodronate, n = 12; placebo, n = 28; HR, 0.44; 95% CI, 0

179 reduction in occurrence of bone metastases (clodronate, n = 63; placebo, n = 80; hazards ratio [HR],

180 re was a significant reduction in mortality (clodronate, n = 98; placebo, n = 129; P =.047) during th

181 e, risedronate, pamidronate, etidronate, and clodronate on apoptosis and signaling kinases.

182 tiinflammatory and antiresorptive effects of clodronate on macrophages and osteoclasts in vivo occur

183 ravenously with either liposome-encapsulated clodronate or empty liposomes prior to and after OBX or

184 phage depletion agent (liposome-encapsulated clodronate) or with a neutrophil depletion agent (cyclop

185 Moreover, clodronate pre-treatment increased durable donor-specifi

186 We found that liposomal clodronate pretreatment of C57BL/6 mice permitted establ

187 asal administration of liposome-encapsulated clodronate prior to bacterial inoculation.

188 epletion of splenic macrophages by liposomal clodronate protects against PIFA-induced chemoresistance

189 Notably, the liposome-encapsulated clodronate reduced the severity of LPS-induced neurodege

190 se changes, whereas depleting monocytes with clodronate resulted in a modest partial inhibition.

191 Macrophage depletion by liposomal clodronate resulted in a reversal of the beneficial effe

192 r bisphosphonates, including pamidronate and clodronate, seem to be ineffective in this setting.

193 was associated with an increase in levels of clodronate-sensitive, phagocytic SiglecF(low) alveolar m

194 rom the fetal cerebral cortex with liposomal clodronate significantly increased the number of neural

195 reating mice with i.v. liposome-encapsulated clodronate, significantly attenuated perfusate cytokine

196 ocyte ablation were used: systemic liposomal clodronate (sLC), inducible depletion using CD11b diphth

197 In either case, liposomal clodronate substantially decreased RBC destruction.

198 Thus, in AIHA, liposomal clodronate therapy may act like a temporary, medicinal s

199 Use of liposomal clodronate to deplete resident AMs (rAMs) resulted in in

200 Mice were treated with liposomal clodronate to investigate the effect of macrophage deple

201 first time the use of liposome-encapsulated clodronate to selectively deplete macrophages during the

202 resulting in improved survival of liposomal clodronate-treated B6 recipients.

203 fa, Il-1beta, Il-10, Cxcl1, and iNos, in the clodronate-treated H. bilis-infected Rag2(-/-) mice comp

204 Injected eyes of IFN-gamma knockout or clodronate-treated macrophage-depleted mice were examine

205 These clodronate-treated mice also had increased expression of

206 tic cells were more numerous in MAFIA versus clodronate-treated mice and flow cytometric analyses of

207 f macrophages in the OE of both sham and OBX clodronate-treated mice were significantly reduced compa

208 When compared with vehicle-treated controls, clodronate-treated non-lupus-prone DBF(1) mice developed

209 caspase-3 in the OE and olfactory nerves of clodronate-treated OBX mice compared to liposome-treated

210 d in extracts from osteoclasts purified from clodronate-treated rabbits.

211 t reduction in bacterial colonization in the clodronate-treated Rag2(-/-) mice.

212 , 1.32+/-0.41 mm(3) in liposome-encapsulated clodronate-treated versus 3.04+/-0.72 mm(3) in saline-tr

213 Although clodronate treatment alone produced a peak level of bloo

214 Clodronate treatment also delayed the resolution of tiss

215 Furthermore, clodronate treatment hastened the onset of proteinuria a

216 ion of monocytes or macrophages by liposomal clodronate treatment or genetic deficiency of macrophage

217 Similarly, depletion of macrophages by clodronate treatment prevented HFD-induced adipose tissu

218 Previous findings of adjuvant clodronate trials in different populations with operable

219 Using phosphate, heparin, clodronate, trypan, and suramin, we demonstrate the util

220 Liposome-encapsulated clodronate was also metabolized to AppCCl2p by rat perit

221 By depleting macrophages using liposomal clodronate, we found that alveolarization defects were s

222 LDD and clodronate were given as a single agent or as combinatio

223 iposomes containing the macrophagicidal drug clodronate were used to deplete conjunctival macrophages

224 t-generation bisphosphonates (etidronate and clodronate) were not suitable for long-term treatment an

225 Therefore, we hypothesized that liposomal clodronate would be a useful agent for treating AIHA.